Hodgkin's lymphoma (HL) survivors are known to be at substantially increased risk of solid cancers (SC). However, no investigation has used multivariate modeling to estimate the relative risk (RR), excess absolute risk (EAR), and cumulative incidence for specific attained ages and ages at HL diagnosis.
INTRODUCTION
Second primary cancers are a major cause of morbidity and mortality among long-term survivors of Hodgkin's lymphoma (HL). 1, 2 There are, however, few estimates of the cumulative incidence of second cancers 25 years after HL diagnosis, and most estimates do not account for competing causes of death. [1] [2] [3] [4] [5] [6] Further, risk estimates often group together survivors of considerably different ages and do not reveal the significant age-related differences in the excess incidence of solid cancers (SC). Evaluation of long-term site-specific risks and changes in risk beyond 20 years of follow-up are sparse, due to the constraints of sample sizes in most series. 4, 6, 7 A better understanding of the age-and sexspecific absolute risks of second cancers would facilitate the development of individualized risk assessment, meaningful communication of risks to HL survivors, and the development of screening strategies to facilitate early detection. No study has used multivariable methods to model changes in the absolute excess risk (EAR) of SC with prolonged follow-up, taking into account the effect of age at HL diagnosis, attained age, time since HL diagnosis, calendar year of HL diagnosis, sex, and initial treatment. Further, age-specific estimates of the cumulative incidence of second cancer among adult HL survivors, adjusted for competing risks and contrasted with the expected incidence in the general population, do not exist.
In this study, we applied for the first time multivariable modeling to a cohort of 18,862 5-year survivors of HL to evaluate the relative risk (RR) and EAR of specific SC change over time for HL survivors diagnosed at specified ages, and to estimate the age-specific cumulative incidence of SC in survivors with prolonged follow-up.
PATIENTS AND METHODS
Patients diagnosed with a first primary HL (years of diagnosis, and who survived at least 1 year after diagnosis (N ϭ 28,421) were identified from nationwide population-based cancer registries in Norway, Sweden, Denmark, Finland, and nine areas of the United States using the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. The SEER Program registries cover approximately 13% of the US population, and include the states of Connecticut (1973ϩ) , Hawaii (1973ϩ) , Iowa (1973ϩ) , New Mexico (1973ϩ), and Utah (1973ϩ), and cover the metropolitan areas of San Francisco-Oakland (1973ϩ), Detroit (1973ϩ), Seattle-Puget Sound (1974ϩ), and Atlanta (1975ϩ). 8, 9 Most analyses were restricted to 5-year HL survivors, including a subgroup of patients described in an earlier report, 5 with extended follow-up. The previous report did not included multivariate modeling. 5 Information on patient vital status, date of death, cause of death, and the occurrence of second invasive cancers was obtained from each cancer registry. Data regarding initial course of therapy (chemotherapy, radiation therapy [RT] , and combined-modality therapy [CMT] ) were provided by all registries except Sweden; data were not available, however, for specific cytotoxic drugs, RT fields, or the use of salvage therapy.
The follow-up period began 1 year after the date of HL diagnosis and ended on the date of death, date of diagnosis of second cancer, or on the study end date (December 31, 2002), whichever occurred first. Personyears (PY) and second cancers were categorized by sex, calendar year of HL diagnosis (1970 to 1984 or 1985 to 1996) , initial treatment modality, registry, and 5-year intervals of attained age, attained calendar year, time since HL diagnosis, and age at HL diagnosis. Cancer incidence rates specific for each registry, sex, and 5-year age and calendar year intervals were multiplied by the corresponding PY at risk to estimate the number of cancer cases expected in each stratum. Ͻ 20  182  1  3,244  1  20-29  1,932  10  24,321  62  30-39  4,524  24  48,095  198  40-49  4,681  25  39,721  304  50-59  3,319  18  21,587  286  Ն 60  4,224  22  23,785  639  Calendar year of diagnosis  1970-1984  9,247  49  113,933  1,142  1985-1997  9,615  51  46,820  348  Registry and year of HL diagnosis  SEER program, 1973-1995  10,270  54  82,269  697  Sweden, 1970-1997  3,129  17  29,601  310  Finland, 1970-1997  2,085  11  18,568  196  Denmark, 1970-1994  1,957  10  17,430  152  Norway, 1970-1995  1,421  8  12,886  135  Time since HL diagnosis, years   ‫ء‬   5-9  7,049  37  75,275  489  10-14  4,907  26  45,906  435  15-19  3,466  18  25,231  319  20-24  2,211  12  11,187  189  25-29  1,059  6  2,950  56  Ն 30  170  1  204  2  Initial treatment  Radiation, no chemotherapy  6,461  34  64,094  625  Chemotherapy, no radiation  4,398  23  28,829  235  Radiation and chemotherapy  2,847  15  20,899  174  Other/unknown  5,156  27  46,931  456 Abbreviations: HL, Hodgkin's lymphoma; SEER, Surveillance, Epidemiology, and End Results database.
‫ء‬
Based on status at the end of follow-up except for person-years, for which patients may contribute to several categories over their follow-up period.
In general, O and E are used to denote observed and expected numbers of SC. O i , E i , and PY i denote observed cases, expected cases, and PY, respectively, in a specified cell of the PY categorization defined in the previous paragraph. Analyses focused on the RR, defined as the ratio of risks in HL patients and the general population, and EAR, defined as the difference in risks in HL patients and the general population and expressed as the number of excess cases per 10,000 PY. Poisson regression methods 10 were used to estimate the RR and EAR as functions of sex, age at HL diagnosis, attained age, and other variables. The statistical expectation of O i was assumed to be E i RR (
, where x is a vector of variables on which the RR or EAR depends. Methods are similar to those used in a study of testicular cancer survivors.
11
For modeling, broad categories of SC were defined based on anatomic site, estimated radiation dose within traditional supradiaphragmatic (mantle) and infradiaphragmatic RT fields (Appendix 1, online only), and whether differences existed in the nature of the dependencies of risk on age at HL diagnosis and attained age. The selected categories were female breast cancer, thyroid cancer, other supradiaphragmatic sites (head and neck, esophageal, and respiratory cancers), and infradiaphragmatic sites (nonesophageal gastrointestinal cancers and urinary cancers). The designation "supradiaphragmatic sites" excluded cancers of the thyroid and female breast. Most analyses were restricted to 5-year survivors, with RRs and EARs pertaining to the period Ն 10 years after HL diagnosis. Two-sided P values are used throughout.
Cumulative risks of a SC were calculated using a competing risk analysis similar to that used in a study of SC after testicular cancer diagnosis, 11 accounting for age at HL diagnosis, attained age, and competing risks from HL mortality, noncancer mortality, and intervening diagnosis of leukemia or non-Hodgkin's lymphoma. Further detail on statistical methods is provided in the Appendix (online only).
RESULTS
A total of 18,862 5-year survivors of HL were identified (Table 1) . Median age at HL diagnosis was 30 years, and median duration of follow-up was 12.2 years (range, 5.0 to 32.9 years). SC were diagnosed in 1,490 patients compared with 625.4 expected (O/E ϭ 2.38; 95% CI, 2.26 to 2.51).
SC risks were found to depend strongly on age at HL diagnosis and attained age, with distinctly different patterns for female breast cancer, supra-and infradiaphragmatic sites, and thyroid cancer. These patterns are depicted by showing the change in risks with advancing attained age for patients diagnosed with HL at ages 20, 30, and 40 years ( Fig 1 and Table 2 ). Although the RR of female breast cancer ( Fig 1A) declined significantly with attained age (P Ͻ .001), the underlying increase in baseline risk with advancing age led to a significant increase in EAR (P Ͻ .001; Fig 1C) , indicating that the burden of excess breast cancer continues to rise with advancing attained age, particularly for young patients. Both the RR and EAR of breast cancer decreased significantly with age at HL diagnosis (P Ͻ .001), although notably Modeling Long-Term SC Risk After HL www.jco.orgboth risk measures remained elevated above expectation among women diagnosed with HL at 30 to 39 years (P Ͻ .001) and among women diagnosed with HL at 40 years and older (P ϭ .07 for RR; P ϭ .04 for EAR).
For supra-and infradiaphragmatic sites (Figs 1B and 1D), there was no significant change in RR (P Ͼ .5) with attained age until ages Ն 60 years, at which point a significant decline was observed (P Ͻ .001). In contrast, the EAR increased strongly with attained age up to about age 70 years (P Ͻ .001) but then decreased (P Ͻ .001). Even with these declines, both the RR and EAR remained significantly elevated above expectation at attained ages 80 years and older (P ϭ .02 for both RR and EAR). The RR and EAR decreased with increasing age at HL diagnosis up to 40 years (P Ͻ .001), after which there was no evidence of further decrease (P Ͼ .5). Both the RR and EAR of supraand infradiaphragmatic cancers remained significantly elevated among patients diagnosed at 40 years and older (P Յ .001). The RR did not differ by sex (P Ͼ .5), but the EAR was significantly larger for men (P Ͻ .001).
Both the RR and EAR for thyroid cancer (data not shown) showed exceptionally strong decreases with age at HL diagnosis (P Ͻ .001). However, in contrast with sites shown in Figure 1 , there was no evidence that either measure depended on attained age (P Ͼ .5).
These results were based on analyses that simultaneously evaluated both age at HL diagnosis and attained age, which is important because these variables are highly correlated. For example, without adjustment for age at HL diagnosis, the EAR for female breast cancer decreased instead of increased with attained age, and without adjustment for attained age, the EAR for supra-and infradiaphragmatic sites increased instead of decreased with age at HL diagnosis.
Modeled RRs for patients diagnosed with HL at age 30 years and, for most sites, attained ages 40 to 60 years are listed in Table 3, Table 4 , and Table 5 . Risks were significantly elevated for all cancer sites evaluated except bladder and prostate. Relative risks greater than tenfold were found for cancers of pleura, soft tissue, and bone, and for cancers of unspecified primary site. The estimated total number of excess SC was 850; 417 (49%) of these occurred in women. The leading sites of excess cancer were the lungs (26% of excess cases), breasts (42% of excess cases in women), and colorectal sites (7% of excess cases).
We sought to identify the attained age at which the absolute risk of screen-detectable cancers (colorectal or breast) for young HL survivors was comparable to that observed among the general population for whom screening may be recommended. The absolute risk of colorectal cancer was 4.5 per 10,000 PY among the general population ages 50 to 54 years in the participating registries (ie, among those for whom colorectal cancer screening would be recommended). By comparison, the absolute risks of colorectal cancer for patients diagnosed with HL at ages 15 or 25 years are comparable or greater by age 40 years (6.1 and 3.9 per 10,000 PY, respectively). Most of the absolute risk arose from colon rather than rectal cancer. The absolute risk of breast cancer among the general population of women ages 50 to 54 years in the participating registries (for whom breast cancer screening is routinely recommended) was 24 per 10,000 PY. Among female patients diagnosed with HL at ages 15 or 25 years, this level of risk was exceeded 10 years after HL diagnosis (34 and 47 per 10,000 PY, by age 25 or 35 years, respectively).
We also examined the association between the RR of SC and several additional variables. The RR for female breast cancer decreased with increased time beyond 10 years from HL diagnosis (P Ͻ .001; Table 4 ), parallel to the decline with attained age as illustrated in Figure  1A . For both the supra-and infradiaphragmatic sites, RR was elevated for all time intervals, with little indication of a trend toward increasing or decreasing RR with latency beyond 10 years of follow-up (P Ͼ .5 and P ϭ .12 for supra-and infradiaphragmatic sites, respectively). Abbreviations: SC, solid cancers; HL, Hodgkin's lymphoma; RR, relative risk.
‫ء‬
The relative risk is modeled as a function of age at HL diagnosis, attained age, and time since HL diagnosis (5-9 years v Ն10 years). For cancers other than female breast and thyroid, RRs are presented for males and females combined and for individuals diagnosed with HL at age 30 years and attained age range 40 to 60 years (10-30 years following diagnosis); the ERR ( ϭ RR-1) for ages 20 and 40 years at HL diagnosis can be calculated by multiplying the reported ERR by 1.79 and 0.56, respectively. †Calculated as the sum of the contributing cancer sites. ‡RR is presented for women diagnosed with HL at age 30 years and attained age 40 years. Refer to Figure 1 and Table 2 for other ages at HL diagnosis and attained ages.
§Includes cancers of the salivary glands, pharynx, tongue, lip, and mouth.
Again, without adjustment for age at HL diagnosis, results would have differed; the RR for supra-and infradiaphragmatic sites would have shown a significant increase with increasing latency beyond 10 years (P ϭ .01), whereas the RR for breast cancer would have shown no evidence of a decline (P ϭ .33).
Significantly increased RRs of cancers of female breast, supra-, and infradiaphragmatic sites occurred in patients treated initially with RT alone, chemotherapy alone, and CMT (Table 5 ). Initial treatment that included RT was associated with significantly increased RR of breast (P ϭ .012) and supradiaphragmatic SC (P Ͻ .001) compared with treatment with chemotherapy alone. For infradiaphragmatic sites, there was no significant association between initial treatment and RR. When comparing HL patients diagnosed from 1970 to 1984 with those patients diagnosed from 1985 to 1996, there was no evidence of a significant change in SC risk in the later time period (Table 5) ; this finding was unchanged when the period analysis was limited to patients whose initial treatment included radiation therapy, although the relative risk of breast cancer was slightly higher in the later time period.
For men diagnosed with HL at ages 20, 30, and 40 years, the 30-year cumulative incidence of SC was 10.5%, 18.3%, and 27.1%, respectively (Fig 2) , compared with 2.4%, 6.9%, and 17.4%, in the general population. For women diagnosed at the same ages, cumulative incidence of SC was 24.3%, 26.1%, and 26.7%, respectively, compared with 4.5%, 8.9% and 15.4%, in the general population. If trends in risks with attained age (Fig 1) continue, the cumulative incidence of second cancer by age 80 years is predicted to be 46%, 40%, and 35% for men diagnosed with HL at ages 20, 30, and 40 years, respectively; corresponding risks for women diagnosed would be 66%, 51%, and 35%.
DISCUSSION
This is the first study to use multivariable modeling to describe the effects of age at HL diagnosis and attained age on both the RR and EAR of SC among HL survivors. After adjusting for age at diagnosis, the EAR of both breast and non-breast SC increased significantly with attained age, with a significant decline in the latter noted among elderly patients, a finding that has not been demonstrated previously. RRs of breast and non-breast SC also showed significant variation with age at diagnosis and attained age. Excess 
‫ء‬
Analyses are adjusted for age at HL diagnosis and presented for an individual diagnosed with HL at age 30 years. Abbreviations: RR, relative risk; SC, solid cancers; RT, radiation therapy; CT, chemotherapy; HL, Hodgkin's lymphoma.
Analyses are limited to 5-year survivors and adjusted for age at HL diagnosis, attained age, and time since HL diagnosis (5-9 years v Ն 10 years). Results are presented for an individual diagnosed with HL at age 30 years for the period Ն 10 years since HL diagnosis.
†RRs are presented for an individual with attained age of 40 years. ‡RRs are presented for an individual with attained age of 40 to 60 years. §Analyses exclude individuals without initial treatment information (see Methods section). ʈAnalyses are limited to the period 5 to 14 years since HL diagnosis because few patients diagnosed after 1985 received follow-up for more than 15 years.
risks were predicted to remain significantly elevated among those patients 80 years and older, indicating that HL survivors likely experience increased risks of SC for life. It is noteworthy that in this large cohort study, unadjusted analyses suggested substantially different temporal patterns of SC risk than adjusted analyses. This may explain why we found little evidence of increasing RR for SC of supra-and infradiaphragmatic sites, and a decrease in RR for female breast cancer with latency beyond 10 years, whereas prior unadjusted analyses found increasing RR of SC with latency Ն 10 years. [3] [4] [5] 7, 12 Similarly, in contrast with unadjusted analyses that have shown that EARs of non-breast SC increase or remain stable with increasing age at HL diagnosis, 4-7,12 we found that after adjusting for attained age the EAR decreased with older age at diagnosis for non-breast SC as well as for female breast cancer.
Age-related variations in baseline and excess risks are reflected in the progressive divergence between the expected and observed cumulative incidence of SC among survivors of different age groups. The excess cumulative incidence of SC was strongly dependent on sex, age at HL diagnosis, and attained age, and was most pronounced for women diagnosed at young ages. Women diagnosed with HL at age 20 were estimated to have a 30-year cumulative incidence of SC that was 20% higher than expected, and they had the potential to experience a 50-year cumulative incidence of 66%. In contrast, young men had a lower incidence of SC, 8% higher than expected at 30 years.
Understanding temporal and age-related trends in SC risk could inform screening recommendations for HL survivors. In North America, colorectal cancer screening is recommended for average-risk adults starting at age 50 years.
13,14 Among young HL survivors, the absolute risk of colorectal cancer was comparable to an average 50-to 54-year-old by age 35 to 40 years, long before screening would generally be recommended. Our results suggest for the first time that among HL survivors, colorectal cancer screening should be considered before the age of routine screening in the general population, although a better understanding of the accuracy of existing screening tests in HL survivors is needed. Similarly, the absolute risk of breast cancer among young female survivors increased to a level comparable to an average 50-year-old woman within 5 to 10 years following HL diagnosis, a finding that supports recommendations to initiate breast cancer screening within this interval. 15 The risk of lung cancer is also elevated among HL survivors, and a recent study suggests that CT screening may increase their quality-adjusted survival, particularly among those survivors who smoke. 16 We did not compare lung cancer risk among HL survivors to that seen among other high risk groups, since we did not have data on patients' smoking habits, and also because appropriate high risk comparison groups have not been clearly established.
The strong role of radiation in the excess risk for SC is demonstrated by the increased risks of breast cancer and supradiaphragmatic cancers in patients whose initial treatment included RT. Similar observations in prior studies 3-6,17-19 have influenced HL management, with greater use of chemotherapy as initial treatment, and more selective use of smaller involved-field RT. [20] [21] [22] It is notable, however, that the risk for cancer at all major evaluated sites was significantly elevated after initial treatment with chemotherapy alone (about 3.3-fold). These findings may be due in part to subsequent RT use not documented in our database, and to the use of alkylating agents, which have been associated with increased risks of lung cancer 17,23 and other SC.
6, 24 We also found no evidence that patients treated after 1984 had a lower risk of all SC taken together than those patients who were diagnosed from 1970 to 1984. However, since this comparison was limited to 5 to 15 years after HL diagnosis, it does not provide a complete assessment of long-term risk. In particular, the transition from extended-mantle RT to smaller-volume involved-field RT occurred well after 1984, 20,21,25-27 and one would not expect the anticipated reduction in SC risk due to smaller RT fields to be apparent in the latter period of this study. These findings highlight the importance of quantifying the risk of chemotherapy-induced cancers, 28 especially in view of carcinogenicity in laboratory animals, 29, 30 and highlight a better understanding of the extent to which the SC risk in HL patients is biologically mediated in ways unrelated to treatment.
19,31
To our knowledge, this is the first study to identify a significantly increased risk of cancer of the pleura (RR ϭ 19.5) following treatment for HL. Previously, only case reports have documented mesothelioma diagnoses, typically more than 10 years after RT for HL. [32] [33] [34] [35] Similarly, few studies have identified a significant increase in the RR of brain cancers among HL survivors. 5, 6 RT fields that encompass lymph nodes in the upper neck may include part of the posterior fossa, delivering an average radiation dose of 0.39 Gy to brain (Appendix Table A1 , online only). Our findings are compatible with evidence that meningiomas and other CNS cancers may develop after lowdose RT. 36, 37 This study has limitations that warrant consideration. We lack detailed comprehensive treatment data that would help refine our SC risk estimates. Although the models in this article describe the dependencies of the RR and EAR on age at HL diagnosis and attained age, they should not be interpreted as defining these patterns precisely. Caution is needed in making predictions of second cancer risk beyond 30 years of follow-up for patients who are young when diagnosed with HL, since the estimated changes in risk seen with advanced attained age were based on those patients diagnosed with HL at older ages.
Nevertheless, our results indicate that while there is a decrease in the risk of non-breast SC among elderly HL survivors, many survivors remain at increased risks for SC for most of their remaining lives. Ongoing research should help to identify HL treatment modifications to reduce SC risk while maintaining efficacy. For current survivors, there is a need to investigate interventions to reduce the morbidity and mortality caused by second cancers and to explore possible genetic modifiers of treatment-related effects.
